{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:01:40Z","timestamp":1778752900259,"version":"3.51.4"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T00:00:00Z","timestamp":1127174400000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1.\u2002The aim of the present study was to compare ecto\u2010nucleotidase activities in rat bisected vas deferens using 1,<jats:italic>N<\/jats:italic><jats:sup>6<\/jats:sup>\u2010etheno(\u03b5)\u2010nucleotides (\u03b5\u2010ATP and \u03b5\u2010AMP) as substrates. Degradation was estimated by measuring the disappearance of the substrate and the appearance of its metabolites using HPLC with fluorescence detection. Incubation of tissue preparations (prostatic or epididymal portions) with 300\u00a0nmol\/L \u03b5\u2010ATP at 37\u00b0C caused a partial disappearance of \u03b5\u2010ATP and appearance of its metabolites (\u03b5\u2010ADP, \u03b5\u2010AMP and \u03b5\u2010adenosine). Incubation at 25\u00b0C reduced \u03b5\u2010ATP degradation more in the prostatic than in the epididymal portion.<\/jats:p><jats:p>2.\u2002Incubation of tissue preparations with \u03b5\u2010AMP at 37\u00b0C resulted in the disappearance of \u03b5\u2010AMP and the appearance of \u03b5\u2010adenosine, which was more pronounced in the epididymal than in the prostatic portion. Incubation at 25\u00b0C reduced \u03b5\u2010AMP degradation more in the epididymal than in the prostatic portion.<\/jats:p><jats:p>3.\u2002Decreasing pH from 7.4 to 6.5 enhanced \u03b5\u2010AMP degradation only in the prostatic portion, whereas increasing pH from 7.4 to 8.5 enhanced \u03b5\u2010AMP degradation in both portions, but more markedly in the epididymal portion. The alkaline phosphatase inhibitors levamisole (10\u00a0mmol\/L) and \u03b2\u2010glycerophosphate (10\u00a0mmol\/L) reduced \u03b5\u2010AMP degradation only in the epididymal portion.<\/jats:p><jats:p>4.\u2002In conclusion, the results of the present study are compatible with the presence, in the bisected rat vas deferens, of an ecto\u2010nucleotidase system that is involved in the degradation of extracellular purines, which may differ between the epididymal and prostatic portions, with the epididymal portion presenting a different and higher capacity to form adenosine.<\/jats:p>","DOI":"10.1111\/j.1440-1681.2005.04252.x","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T09:37:54Z","timestamp":1127209074000},"page":"721-727","source":"Crossref","is-referenced-by-count":10,"title":["REGIONAL DIFFERENCES IN EXTRACELLULAR PURINE DEGRADATION IN THE PROSTATIC AND EPIDIDYMAL PORTIONS OF THE RAT VAS DEFERENS"],"prefix":"10.1111","volume":"32","author":[{"given":"Carmen","family":"Diniz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Fresco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,9,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(91)90587-I"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1978.sp012486"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.035113"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60717-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2330309"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2850345"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7696(08)62487-0"},{"key":"e_1_2_6_9_2","first-page":"178","article-title":"Pharmacological characterization of heterologously expressed ATP\u2010gated cation channels (P2x purinoceptors)","volume":"48","author":"Evans RJ","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2299(199611\/12)39:3\/4<262::AID-DDR5>3.0.CO;2-P"},{"key":"e_1_2_6_11_2","first-page":"413","article-title":"Receptors for purines and pyrimidines","volume":"50","author":"Ralevic V","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-8673.1992.tb00390.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02926-6"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01906-4"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.175.4022.646"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2500369"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(84)90352-X"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81276-1"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.37.5.545"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703750"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2004.07.005"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/387076a0"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.2003.03808.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.2001.03460.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(97)00126-5"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00171048"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2680.1999.00129.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00789-X"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703271"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj1460625"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.2000.t01-1-00467.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958020-00002"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(95)02053-5"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1986.tb11169.x"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2005.04252.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2005.04252.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T23:29:54Z","timestamp":1696894194000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2005.04252.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1111\/j.1440-1681.2005.04252.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2005.04252.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}